Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Barclays PLC acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $255,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Bicara Therapeutics in the 3rd quarter worth about $309,000. Wellington Management Group LLP bought a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $19,458,000. Soros Fund Management LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at approximately $509,000. Samsara BioCapital LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at approximately $891,000. Finally, RA Capital Management L.P. acquired a new stake in Bicara Therapeutics in the third quarter valued at approximately $177,169,000.

Analysts Set New Price Targets

A number of research analysts have issued reports on BCAX shares. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright began coverage on shares of Bicara Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $42.00 price target on the stock. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Trading Down 1.4 %

BCAX opened at $16.69 on Monday. The stock’s 50-day simple moving average is $20.10. Bicara Therapeutics Inc. has a twelve month low of $16.01 and a twelve month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Equities analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.